Clinical trial
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RT036 in Participants With Advanced Malignant Solid Tumors
NCT07844447 is registered in ClinicalTrials.gov with Shanghai Ruotuo Biosciences Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RT036 in Participants With Advanced Malignant Solid Tumors
- Lead sponsor
- Shanghai Ruotuo Biosciences Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- October 30, 2026
- Completion date
- October 30, 2029
- Enrollment
- 308 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid tumours